Y. Hong

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

P. LoRusso, G. Schwartz, M. Gounder, 2020 .

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer.

J. Desai, E. Van Cutsem, J. Tabernero, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.

J. Moon, D. Jin, E. Choi, 2013, Neoplasma.